Crinetics Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
Checking your notes…
(in thousands)
| Common Stock | CommonStock andPaid-InCapital | AccumulatedOtherComprehensiveIncome (Loss) | AccumulatedDeficit | Stock Held in Trust | TotalStockholders’Equity | |
|---|---|---|---|---|---|---|
| Shares | ||||||
| Balance at January 1, 2023 | 53,877 | $759,432 | $(3,931) | $(439,173) | $— | $316,328 |
| Issuance of common stock, net of transaction costs | 12,787 | 369,080 | — | — | — | 369,080 |
| Issuance of common stock upon vesting of restricted stock units | 81 | — | — | — | — | — |
| Exercise of stock options | 1,283 | 20,091 | — | — | — | 20,091 |
| Stock issued under Employee Stock Purchase Plan | 147 | 2,291 | — | — | — | 2,291 |
| Stock-based compensation | — | 40,937 | — | — | — | 40,937 |
| Comprehensive income | — | — | 4,908 | — | — | 4,908 |
| Net loss | — | — | — | (214,529) | — | (214,529) |
| Balance at December 31, 2023 | 68,175 | 1,191,831 | 977 | (653,702) | — | 539,106 |
| Issuance of common stock, net of transaction costs | 21,986 | 970,048 | — | — | — | 970,048 |
| Issuance of common stock upon vesting of restricted stock units | 249 | — | — | — | — | — |
| Exercise of stock options | 2,294 | 40,463 | — | — | — | 40,463 |
| Stock issued under Employee Stock Purchase Plan | 222 | 4,224 | — | — | — | 4,224 |
| Stock-based compensation | — | 69,386 | — | — | — | 69,386 |
| Comprehensive loss | — | — | (14) | — | — | (14) |
| Net loss | — | — | — | (298,408) | — | (298,408) |
| Balance at December 31, 2024 | 92,926 | 2,275,952 | 963 | (952,110) | — | 1,324,805 |
| Issuance of common stock upon vesting of restricted stock units | 415 | — | — | — | — | — |
| Exercise of stock options | 2,028 | 35,402 | — | — | — | 35,402 |
| Stock issued under Employee Stock Purchase Plan | 206 | 5,219 | — | — | — | 5,219 |
| Stock-based compensation | — | 91,024 | — | — | — | 91,024 |
| Stock held in trust under deferred compensation plan | — | 112 | — | — | (112) | — |
| Other | — | 48 | — | — | — | 48 |
| Comprehensive income | — | — | 902 | — | — | 902 |
| Net loss | — | — | — | (465,317) | — | (465,317) |
| Balance at December 31, 2025 | 95,575 | $2,407,757 | $1,865 | $(1,417,427) | $(112) | $992,083 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.